The global neurological biomarkers market size accounted for USD 9.14 billion in 2024, grew to USD 10.32 billion in 2025 and is expected to be worth around USD 30.77 billion by 2034, registering a healthy CAGR of 12.90% between 2024 and 2034. The North America neurological biomarkers market size is calculated at USD 3.66 billion in 2024 and is estimated to grow at a fastest CAGR of 13.02% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Neurological Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Neurological Biomarkers Market Revenue and Volume, by Type, 2024-2034
8.1.1 Genomic
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Proteomic
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Metabolomic
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Imaging
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Neurological Biomarkers Market Revenue and Volume, by Application, 2024-2034
9.1.1. Alzheimer’s Disease
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Parkinson’s Disease
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Multiple Sclerosis
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Autism Spectrum Disorder
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Neurological Biomarkers Market Revenue and Volume, by End-use, 2024-2034
10.1.1. Hospital & Hospital Laboratories
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Independent clinical diagnostic centers
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Research Organizations & Others
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.1. Rules-Based Medicin
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Alseres Pharmaceuticals, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Quanterix
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Banyan Biomarkers, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. DiaGenic ASA
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Johnson & Johnson Services, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bio-Rad Laboratories, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Thermo Fischer Scientific, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Abbott
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample